Nanobiotix (NBTX) Fundamental Analysis: Revenue, Earnings & Valuation

2.36 / 10

Underperform

Fundamental analysis rates NBTX as Underperform with a 2.4/10 score. Revenue growth is exceptional (186.8% YoY) and gross margin hits 100%, but fixed‑asset turnover is low and cost‑of‑sales ratio is high, indicating efficiency and profitability challenges.

Analysis Checks(5/6)

Total operating revenue (YoY growth rate %)

Value186.77

Score2/3

Weight23.23%

1M Return-1.06%

Inventory turnover ratio

Value37.77

Score2/3

Weight27.07%

1M Return-1.21%

Gross profit margin (%)

Value100.00

Score2/3

Weight-43.90%

1M Return1.69%

Income tax / Total profit (%)

Value-0.11

Score2/3

Weight-25.74%

1M Return1.04%

Fixed assets turnover ratio

Value4.79

Score1/3

Weight26.85%

1M Return-1.24%

Cost of sales ratio (%)

Value73.08

Score2/3

Weight92.49%

1M Return-4.42%

Is NBTX undervalued or overvalued?

NBTX scores 2.36/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -73.52% net margin, -58.75 P/E ratio, -16.66 P/B ratio, and 60.63% earnings growth, these metrics solidify its Underperform investment rating.